Previous Close | 58.6500 |
Open | 58.6900 |
Bid | 59.1200 x 600 |
Ask | 59.1300 x 800 |
Day's Range | 58.4950 - 59.2850 |
52 Week Range | 42.8800 - 64.6000 |
Volume | 3,504,967 |
Avg. Volume | 7,013,275 |
Market Cap | 103.313B |
Beta | 1.67 |
PE Ratio (TTM) | 219.93 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.12 (1.90%) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Key stock index funds rose Thursday as the FANG stocks and other big-cap techs powered big gains in the tech-heavy PowerShares QQQ Trust.
Abbott Laboratories (ABT) is a developer and manufacturer of a broad and diversified line of healthcare products. Its business segments include pharmaceutical products, diagnostic products, nutritional products, and cardiovascular and neuromodulation products.
Over the last month, BSX stock has registered a rise of ~4.2%. The company came out on top in patent infringement litigation against Edwards Lifesciences (EW), for which a hearing is scheduled in May at the German Court of Appeal. On April 16, Boston Scientific announced its acquisition of Nvision Medical Corporation for a cash payment of $150 million and an additional milestone-based payment over the next four years amounting to $125 million.
On April 25, Boston Scientific (BSX) plans to announce its 1Q18 earnings results—the quarter that ended on March 31. According to Wall Street analysts’ estimates, the company’s 1Q18 revenues are expected to come in at $2.34 billion, representing YoY (year-over-year) growth of ~8.4%.
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
also promised British citizenship to children of Windrush generation migrants who did not currently hold the status and waived the fees involved. “I want to enable the Windrush generation to acquire the status that they deserve — British citizenship — quickly, at no cost and with proactive assistance through the process,” Ms Rudd told the House of Commons. Several MPs warned that there were looming scandals with families from other former parts of the British empire who had automatically received the right to remain in the UK under legislation passed in 1971 but whose right to do so was now being questioned.
UK home secretary Amber Rudd on Monday made the most concerted effort so far to draw a line under the scandal over the treatment of the Windrush generation of Caribbean immigrants, announcing a package ...
Top Analyst Reports for Goldman Sachs, Abbott & Altria
Edwards Lifesciences, Medtronic, Boston Scientific and Abbott Laboratories are duking it out for a share of the fast-growing heart-valve replacement market.
Shares of Abbott Laboratories dipped early Wednesday — despite its broad first-quarter beat — on pharmaceutical sales that lagged Wall Street's expectations by nearly 4%.
ABT earnings call for the period ending March 31, 2018.
rose just 0.06% after posting a 38% increase in first-quarter profit. S&P 500 companies are expected to post an 18.6% increase in first-quarter profit, the biggest rise in seven years, according to Thomson Reuters.
Jim Cramer and our other experts look at banks, three sections to trade, and REITs.
The size of Abbott Laboratories (NYSE:ABT), a US$104.43B large-cap, often attracts investors seeking a reliable investment in the stock market. Doing business globally, large caps tend to have diversified revenueRead More...
Some analysts also said a 6.9 percent rise in organic sales, which excludes the impact of foreign currency and certain divestitures and acquisitions, was just shy of a roughly 7 percent expected by investors. Thomson Reuters I/B/E/S had no consensus estimate for the organic sales.
This is an increase over its earnings per share of 48 cents from the same time last year. It also beat out Wall Street’s earnings per share estimate of 58 cents for the period. Net income reported by Abbott Laboratories in the first quarter of 2018 came in at $418 million.
Some analysts also said a 6.9 percent rise in organic sales, which excludes the impact of foreign currency and certain divestitures and acquisitions, was just shy of a roughly 7 percent expected by investors. Thomson Reuters I/B/E/S had no consensus estimate for the organic sales.
continuous glucose monitoring system FreeStyle Libre is off to a strong start. The debut of Libre, which was approved for sale by the U.S. Food and Drug Administration last September, "has gone exceptionally well," said Abbott chairman and CEO Miles White on an earnings call on Wednesday, April 18. FreeStyle Libre, which was initially launched in Europe in 2014, already has a little over 50,000 users in the U.S., according to White.
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.
Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.
Abbott sees full year earnings of between $2.80 to $2.90 a share after a solid first quarter that topped Wall Street forecasts.